Storia in 3 fonti

Hanmi inks $1.26b licensing deal with Eli Lilly

Hanmi Pharmaceutical said Monday it has clinched an outlicensing contract with Eli Lilly for sonefpeglutide, its long-acting glucagon-like peptide 2, or GLP-2,

Raccontata da

adnkronos.com

koreaherald.com

pharmaceutical-technology.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

koreaherald.comStai leggendo1 g fa

Hanmi inks $1.26b licensing deal with Eli Lilly

Hanmi Pharmaceutical has licensed sonefpeglutide, its GLP-2 drug candidate built on the Lapscovery long-acting platform, to Eli Lilly in a deal worth up to $1.26B ($75M upfront, $1.19B in milestones), with Lilly gaining worldwide rights excluding Korea. The deal signals Lilly's continued expansion into the GLP space beyond GLP-1, confirming long-acting peptide platforms as a high-value M&A and licensing target for pharma majors.

originale

pharmaceutical-technology.com1 g fa

Lilly, Hanmi sign $1.26bn licensing deal for sonefpeglutide

Eli Lilly and Company has entered into a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide, worldwide excluding Korea.

Leggi questa versione → originale

adnkronos.com1 g fa

Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)

Hanmi Pharm signed a licensing deal with Eli Lilly for sonefpeglutide (LAPSGLP-2 analog), with $75M upfront and up to $1.26B in milestone payments; Lilly gains worldwide rights excluding Korea. The deal signals Lilly's expanding bet beyond GLP-1 into GLP-2 biologics for intestinal indications, a space with limited competition and high unmet need in rare diseases like short bowel syndrome.

Leggi questa versione → originale

Timeline cronologica

lunedì 1 giugno 2026·adnkronos.com
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)
Lilly licenses Hanmi's sonefpeglutide(LAPSGLP-2 analog) for multiple indications
lunedì 1 giugno 2026·koreaherald.com
Hanmi inks $1.26b licensing deal with Eli Lilly
Hanmi Pharmaceutical said Monday it has clinched an outlicensing contract with Eli Lilly for sonefpeglutide, its long-acting glucagon-like peptide 2, or GLP-2,
lunedì 1 giugno 2026·pharmaceutical-technology.com
Lilly, Hanmi sign $1.26bn licensing deal for sonefpeglutide
Eli Lilly and Company has entered into a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate,…